http://www.globenewswire.com/news-release/2020/09/03/2088474/0/en/Auris-Medical-Announces-Positive-Interim-Data-from-TRAVERS-Phase-2-Study-with-AM-125-in-Vertigo.html
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
September 03, 2020 08:30 ET | Source: Auris Medical AG
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trial
Improvement 1.9 to 2.4 times greater with highest dose than with placebo
Trial to proceed with Part B to test AM-125 10 and 20 mg vs. placebo
Hamilton, Bermuda, September 3, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced positive top-line data from the interim analysis of its Phase 2 “TRAVERS” trial with intranasal betahistine in vertigo (AM-125).
